Risk of Psychotropic Drug Interactions in Real World Settings: a Pilot Study in Patients with Schizophrenia and Schizoaffective Disorder


Sengul M. C. B. , Karadag F. , Sengul C., Karakulah K., Kalkanci O., Herken H.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.24, sa.3, ss.235-247, 2014 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 24 Konu: 3
  • Basım Tarihi: 2014
  • Doi Numarası: 10.5455/bcp.20140311041445
  • Dergi Adı: KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
  • Sayfa Sayıları: ss.235-247

Özet

Objective: The rate of polypharmacy is increasing in patients with psychotic disorders. Polypharmacy is defined as the concomitant use of two or more drugs at a time. As most psychotropic medications are metabolized via the cytochrome enzyme system, it is easy to predict that polypharmacy will increase the risk of drug-drug interactions. This study was planned to evaluate the interaction risks of medications used by patients with a diagnosis of schizophrenia and schizoaffective disorder.